Headache prophylaxis with BoNTA: Patient characteristics

Headache

Volumn 50, Issue 1, 2010, Pages 63-70

  Silberstein, Stephen D ^a   Marmura, Michael J ^a   Shaw, James ^b   Yu, Shengsheng ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Botulinum toxin; Chronic daily headache; Chronic migraine; Medication overuse headache; MIDAS

Indexed keywords

BOTULINUM TOXIN A; TRIPTAN DERIVATIVE;

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; HEADACHE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PAIN ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; STRUCTURED QUESTIONNAIRE; TRANSFORMED MIGRAINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE DISORDERS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROTOXINS; PAIN MEASUREMENT; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT FAILURE; YOUNG ADULT;

EID: 74249118422     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01481.x     Document Type: Article

References (40)

1. Carson AJ, Ringbauer B, MacKenzie L, Warlow C, Sharpe M. Neurological disease, emotional disorder, and disability: They are related: A study of 300 consecutive new referrals to a neurology outpatient department. J Neurol Neurosurg Psychiatry. 2000 68 : 202 206.
2. World Health Organization. World Health Organization, editor. Geneva, Switzerland, World Health Organization. 2-12-0007. Headache disorders. Fact sheet No. 277. 2004. Available at: http://www.who.int/mediacentre/factsheets/ fs277/en/ (accessed February 12, 2007).
3. Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near-daily headaches: Proposed revisions to the IHS criteria. Headache. 1994 34 : 1 7.
4. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 27 : 193 210.
5. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: Prevalence, risk factors, and biannual follow-up. Neurology. 2000 54 : 314 319.
6. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001 5 : 529 536.
7. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998 38 : 497 506.
8. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the Migraine Disability Assessment (MIDAS) Questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2003 43 : 336 342.
9. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache. 2001 41 : 573 578.
10. Wang SJ, Fuh JL, Lu SR, Juang KD. Quality of life differs among headache diagnoses: Analysis of SF-36 survey in 901 headache patients. Pain. 2001 89 : 285 292.
11. D'Amico D, Usai S, Grazzi L, et al. Quality of life and disability in primary chronic daily headaches. Neurol Sci. 2003 24 (Suppl. 2 97 100.
12. Bigal ME, Lipton RB, Tepper SJ, Rapoport AM, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004 63 : 843 847.
13. Mathew NT. Chronic refractory headache. Neurology. 1993 43 (6 Suppl. 3 26 33.
14. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002 59 : 1011 1014.
15. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003 43 : 171 178.
16. Mathew NT. The prophylactic treatment of chronic daily headache. Headache. 2006 46 : 1552 1564.
17. Conway S, Delplanche C, Crowder J, Rothrock J. Botox therapy for refractory chronic migraine. Headache. 2005 45 : 355 357.
18. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Headache. 2005 45 : 293 307. (Pubitemid 40530193)
19. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005 80 : 1126 1137.
20. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache. 2005 45 : 315 324.
21. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004 24 (Suppl. 1 1 160.
22. Headache Classification Committee, Olesen J, Bousser MG, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 26 : 742 746.
23. Tepper SJ. Debate: Analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is a cause of chronic daily headache. Headache. 2002 42 : 543 547.
24. Dodick DW. Debate: Analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is not a cause of chronic daily headache. Headache. 2002 42 : 547 554.
25. Lipton RB, Bigal ME. Chronic daily headache: Is analgesic overuse a cause or a consequence? Neurology. 2003 61 : 154 155.
26. Silberstein S, Tfelt-Hansen P, Dodick D, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalagia. 2008 28 : 484 495.
27. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache. 2008 48 : 201 209.
28. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001 41 : 854 861. (Pubitemid 33043148)
29. Hunfeld JA, Passchier J, Perquin CW, Hazebroek-Kampschreur AA, van Suijlekom-Smit LW, van der Wouden JC. Quality of life in adolescents with chronic pain in the head or at other locations. Cephalalgia. 2001 21 : 201 206. (Pubitemid 32589036)
30. Tenhunen K, Elander J. A qualitative analysis of psychological processes mediating quality of life impairments in chronic daily headache. J Health Psychol. 2005 10 : 397 407.
31. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986 2 : 245 247.
32. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987 2 : 237 254.
33. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005 26 : 785 793.
34. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003 43 (Suppl. 1 9 15.
35. Oshinsky ML, Pozo-Rosich P, Luo J, Hyman S, Silberstein S. Botulinum toxin type A blocks sensitization of neurons in the trigeminal nucleus caudalis. Cephalalgia. 2004 24 : 781.
36. Dodick D, Silberstein S. Central sensitization theory of migraine: Clinical implications. Headache. 2006 46 (Suppl. 4 S182 S191.
37. Goadsby PJ. Migraine pathophysiology. Headache. 2005 45 (Suppl. 1 S14 S24.
38. Strassman AM, Levy D. Response properties of dural nociceptors in relation to headache. J Neurophysiol. 2006 95 : 1298 1306.
39. Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache. 2006 46 (Suppl. 1 S39 S44.
40. Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006 46 (Suppl. 1 S3 S8.